SPECIAL FEATURES

CCR 20th Anniversary Commentary

493  CCR 20th Anniversary Commentary: Radioactive Drones for B-cell Lymphoma
Susan J. Knox and Ronald Levy

CCR Translations

495  Novel Targets in Head and Neck Cancer: Should We Be Optimistic?
Gabriel S. Krigsfeld and Christine H. Chung
See related article, p. 632

Molecular Pathways

Michelle Cicchini, Vassiliki Karantza, and Bing Xia

505  Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem Cells
Verline Justilien and Alan P. Fields

Special Report

514  Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology

Review

526  HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma
Netanya I. Pollock and Jennifer R. Grandis

CANCER THERAPY: CLINICAL

534  Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans

544  Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Han Sang Kim, Hyeong Ju Kwon, Inkyung Jung, Mi Ran Yun, Myung-Ju Ahn, Byung Woog Kang, Jong-Wu Sun, Sung Bae Kim, Dok-Hyun Yoon, Keon Uk Park, Se-Hoon Lee, Yoon Woo Koh, Se Hun Kim, Eun Chang Choi, Dong Hoe Koo, Jin Hee Sohn, Bomi Kim, Nak-Jung Kwon, Hwan Jung Yun, Min Goo Lee, Ji Hyun Lee, Ta-Eun Kim, Hye Ryun Kim, Joo Hang Kim, Soonmyung Paik, and Byoung Chul Cho

553  First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor 1 Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

PERSONALIZED MEDICINE AND IMAGING

561  The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer


DNA Repair Mutations and Outcomes in Ovarian Cancer—Letter

Robert A. Soslow

DNA Repair Mutations and Outcomes in Ovarian Cancer—Response

Elizabeth M. Swisher, Barbara M. Norquist, Kathryn P. Pennington, Mara H. Rendi, and Rochelle L. Garcia

Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

Correction: HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer

Correction: Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors